Lucid Diagnostics Inc.

Lucid Diagnostics Inc.

LUCDNYSE / NASDAQHealthcareSmall cap

$0.37-$0.01 (-3.4%)

Last close · Data as of Nov 20, 2026

Market cap
$194.6M
Revenue
$4.7M
Net margin
-1498.3%
ROCE
299.8%

-63.4% over the last year

Lucid Diagnostics Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+6.0%
3M
-61.1%
6M
-62.7%
1Y
-63.4%
5Y
-96.0%

52-week range

Day change -$0.01 (-3.4%) from $0.39 to $0.37 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in LUCD, bought on each weekday since 2021.

News & filings

What Lucid Diagnostics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 58.0 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue more than doubled a year on average over three years.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.

Read moreShow less

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Sector
Healthcare
Shares outstanding
131.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$194.6M
P/B
17.8x
EV / Sales
39.4x
P/S
41.3x
52-week high
$1.47
52-week low
$0.33

Profitability

Operating margin
-1053.9%
Net margin
-1498.3%
EBITDA margin
-1212.7%
ROE
-645.1%
ROCE
299.8%
ROIC
-2233.6%
ROA
-174.5%
Asset turnover
0.12

Growth

Revenue
$4.7M
Revenue growth, 1Y
8.3%
Revenue CAGR, 3Y
132.0%
Net profit growth, 1Y
27.4%
Free cash flow
-$46.7M

Solvency

Current ratio
1.31
Debt / Equity
2.36
Debt / Assets
0.64
CFO / Net profit
0.66
Cash / Market cap
17.8%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$4.7M
Cost of revenue$6.7M
Gross profit-$2.0M
Operating expenses$47.7M
Research and development$5.7M
Selling, general and administrative$41.6M
Operating income-$49.6M
Interest and other-$8.4M
Pretax income-$58.0M
Tax and other$0.00
Net income-$58.0M

Revenue and net profit

Revenue grew 8.3% in FY2025; net profit is the dashed line.

Lucid Diagnostics Inc. revenue and net profit by fiscal year
Lucid Diagnostics Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$377.0k-$56.2M
FY2023$2.4M-$52.7M
FY2024$4.3M-$45.5M
FY2025$4.7M-$58.0M

Cash flows

FY2025: -$46.5M from operations, -$46.7M free after investment (dashed).

Lucid Diagnostics Inc. operating and free cash flow by fiscal year
Lucid Diagnostics Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$29.7M-$30.6M
FY2023-$32.8M-$33.0M
FY2024-$44.1M-$44.8M
FY2025-$46.5M-$46.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$4.7M+8.3%1Y
EBITDA
-$57.1M
Net profit
-$58.0M
Cash from operations
-$46.5M
Free cash flow
-$46.7M
Revenue CAGR, 3Y
132.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$4.7M-$57.1M-$58.0M-$46.7M133.9%+8.3%+27.4%

Monthly returns

Month-by-month returns of LUCD across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$40.4M
Liabilities$29.5M
Equity$10.9M
Paid-in capital$230.9M
Retained earnings-$274.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; LUCD highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Lucid Diagnostics Inc. (this company)39.4x

Not shown (no positive earnings and no EV / Sales): Nkarta, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Lucid Diagnostics Inc.LUCDthis company$194.6M—17.8x-645.1%—
TriSalus Life Sciences, Inc.TLSI$202.7M-5.2x-6.0x115.8%-6.6x
Embecta Corp.EMBC$202.3M2.1x-0.3x-14.6%4.9x
Alector, Inc.ALEC$201.0M—6.6x-466.3%—
Nkarta, Inc.NKTX$198.2M—0.6x-33.3%—
Anika Therapeutics, Inc.ANIK$196.8M-18.1x1.4x-7.6%-31.1x
Cartesian Therapeutics, Inc.RNAC$192.4M-1.5x-1.5x103.2%-1.0x
KORU Medical Systems, Inc.KRMD$190.2M-72.1x11.2x-15.5%-85.5x
Tonix Pharmaceuticals Holding Corp.TNXP$189.4M-1.5x0.8x-50.6%0.1x
Peer median—-3.3x0.7x-15.1%-3.8x

Year-to-date ROI

LUCD since 1 January, against earlier years.

Historical volatility

LUCD's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Lucid Diagnostics Inc. operating margin by fiscal year
Lucid Diagnostics Inc. operating margin by fiscal year
DateOperating margin
FY2022-14802.6%
FY2023-1995.1%
FY2024-1058.6%
FY2025-1053.9%
LineFY2025
Cost of revenueCost Of Revenue$6.7M
Gross profitGross Profit-$2.0M
Operating expensesOperating Expense$47.7M
Research and developmentResearch And Development$5.7M
Depreciation and amortisationDepreciation And Amortization In Income Statement$420.0k
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$420.0k
Amortization$420.0k
Amortisation of intangiblesAmortization Of Intangibles Income Statement$420.0k
Total expensesTotal Expenses$54.4M
Pretax incomePretax Income-$58.0M

Learn while you research

Academy chapters picked for Lucid Diagnostics Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 2.36 is elevated, understand what that means for solvency.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →